Clinical Validation of a Plasma Donor-derived Cell-free DNA Assay to Detect Allograft Rejection and Injury in Lung Transplant

A Novel Donor-Derived Cell-Free DNA Assay for the Detection of Acute Rejection in Heart Transplantation

Association between total cell free DNA and SARS-CoV-2 in Kidney Transplant Patients: A Preliminary Study

Reusing, et al. 2022, Transplant Proceedings

Dd-cfDNA Shows High Sensitivity for the Diagnosis of Pancreas Graft Rejection in Simultaneous Pancreas-Kidney Transplantation

Ventura-Aguiar, et al. 2022, Transplantation

Prospera Kidney General Nephrology Brochure

Prospera is powered by highly optimized, proprietary cell-free DNA (cfDNA) technology. As part of your tool kit, Prospera assesses all types of kidney transplant rejection with great precision.

Prospera Heart Physician Brochure

Why Prospera With Biopsy Brochure

The Prospera non-invasive blood test can comprehensively identify all types of active rejection with great precision.

Prospera Patient Brochure

Prospera uses revolutionary tech to enhance the patient and physician’s ability to assess otherwise undetected rejection events that might lead to kidney loss.

Prospera Patient Billing Guide

Natera welcomes all insurance plans. We’re here with you at every step.

Prospera + Renasight Overview

With Natera’s precise DNA analysis, you can effectively manage and provide the best available care to all your kidney patients.

Prospera Lung Physician Brochure

Why Prospera Surveillance Brochure

The Prospera non-invasive blood test can comprehensively identify all types of active rejection with great precision.